



2022: a pivotal year for Extens, the leading investor in digital health, with EUR 100 million in fundraising and 3 new investments.

Paris, 18 January 2023 – **Extens**, the investment fund dedicated to healthcare software and data, had a particularly dynamic year in 2022, following on from 2021, with 3 new investments, 3 reinvestments, 6 add-ons, the exit of Discngine and the closing of its Fund III at EUR 106 million. Extens totals 21 portfolio companies at the end of 2022.

3 new investments, 3 reinvestments, 6 add-ons, and 2 exits

In 2022, Extens invested in three new companies: Canal Santé, an online training organisation for healthcare professionals; Opta LP, a publisher of planning and optimisation solutions for healthcare professionals; and Medelse, a platform that connects healthcare professionals working in private practice with healthcare institutes looking for staff on an ad hoc basis.

In addition to these investments, three reinvestments were completed to support add-ons: Sofia Développement, a publisher of management solutions for the liberal paramedical professions; Horizontal Software, which deploys time management (TAM), recruitment (ATS), and training evaluation tools in the medical sector; and Hoppen, a specialist in patient care for hospitals.

6 additional add-ons have enhanced the value of Extens' portfolio companies, completing their respective offers or increasing their hold on the market: Bow Médical (1), the anaesthesia software publisher; Horizontal Software (1), Hoppen (2) and Sofia Développement (2).

Sofia Développement group welcomed a new investor in 2022 to accelerate its growth trajectory, after being supported by Extens since 2017. Extens choose to renew its confidence in the group, after being deeply involved with the management teams. A strong conviction that illustrates Extens' DNA.

The year 2022 was finally marked by the exit of Discngine, sold to Canadian Chemical Computing Group after five years of collaboration with Extens and the tripling of its turnover.

The impact of Extens in the healthcare sector

At the end of 2022, the numbers associated with Extens' portfolio companies underline the impact of the development strategies implemented by the fund. The average growth rate of Extens' portfolio companies in 2022 was between 20% and 30%, bringing the cumulative turnover to EUR 178 million. These companies employ 1,570 people and deploy their solutions in 85 countries.

A strengthened team

Extens' success is based, after two recruitments in 2022, on a team of 12 professionals with both investment and entrepreneurial profiles. In 2022, Extens structured its investment team recruiting Charles Bourgain, Investment Director, and Vincent Céré, Analyst. Valentine Deramecourt, previously Investment Director, has been promoted to Partner.

Leading investor in the digital transformation of the healthcare system

Extens, through the development of digital solutions dedicated to the medical sector, is building tomorrow's digital health. The fund reaffirms its desire to improve the healthcare system with a strong operational support.

To address this societal challenge, Extens will continue to deploy Fund III in 2023, which amounts to over EUR 100 million. A sixth investment and a new add-on are being closed to start the year.

Portfolio companies will draw on an expanded network of experts to help them take their development to the next level. New reinforcements are preparing to join Extens to provide more guidance and support to management teams.

Finally, Extens will also be strengthening its team to enter a new stage of its development and prepare to raise its coming funds.



Extens is France leading digital health investment fund. Extens acts as a reference investor, mainly in France and Western Europe, by injecting up to EUR 15 million into SMEs that generate over EUR 3 million in revenue and EBITDA positive. The team consists of 12 professionals from the private equity and healthcare industries. Thanks to its in-depth expertise in the digital health ecosystem, Extens aims to turn today's players into tomorrow's champions, by improving their value-creation potential, in the interest of the companies, their teams, their shareholders, and the healthcare system. To date, Extens has invested in 21 companies, including Enovacom, a publisher of interoperability software; Kayentis, software for collecting and analysing patient data for clinical trials; Teranga, a publisher of a business platform for the medico-social sector; Sofia Développement, a publisher of management solutions for the liberal paramedical professions and care centres.

For more information, please visit: <https://www.extens.eu>

If you have any questions, please contact:

- **Thomas Ploquin** – thomas.ploquin@extens.eu – 01.88.40.16.90